<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04060459</url>
  </required_header>
  <id_info>
    <org_study_id>ThirdMMUa</org_study_id>
    <nct_id>NCT04060459</nct_id>
  </id_info>
  <brief_title>Paclitaxel-binding Albumin and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer</brief_title>
  <official_title>Paclitaxel-binding Albumin and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer - A Single-center, Single-arm and Stage II Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study of Paclitaxel-binding albumin, Cisplatin as neoadjuvant chemotherapy
      in patients with muscle-invasive urothelial carcinoma of the bladder. Patients with muscle
      invasive urothelial carcinoma who are candidates for radical cystectomy will be enrolled.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Pathologic Complete Response Rate (&lt;pT0) of Neoadjuvant Paclitaxel-binding albumin and Cisplatin in Patients With Muscle-invasive Bladder Cancer.</measure>
    <time_frame>2 years</time_frame>
    <description>Complete pathologic response to neoadjuvant GCS is the primary endpoint is defined as the absence of carcinoma (pT0 disease) and the absence of microscopic lymph node metastases (N0) on the final cystectomy specimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Pathologic Response Rate (&lt;pT2) of Neoadjuvant Paclitaxel-binding albumin and Cisplatin in Patients With Muscle-invasive Bladder Cancer.</measure>
    <time_frame>2 years</time_frame>
    <description>is defined as the absence of muscle invasive carcinoma (&lt;pT2 disease) and the absence of microscopic lymph node metastases (N0) on the final cystectomy specimen</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment plan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel-binding albumin 260 mg/m2，d1，ivgtt；cisplatin 75 mg/m2，d1，ivgtt</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel-binding albumin</intervention_name>
    <description>Paclitaxel-binding albumin 260 mg/m2，d1，ivgtt；cisplatin 75 mg/m2，d1，ivgtt</description>
    <arm_group_label>Treatment plan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years.

          2. Patients must have histologically confirmed resectable（stage T2，T3 and T4a） urothelial
             carcinoma following 2017 V8 AJCC，including renal pelvic carcinoma，ureteral
             carcinoma，bladder carcinoma and urethral carcinoma.

          3. There was at least one measurable tumor lesion following RECIST 1.1.

          4. Treatment naïve.

          5. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

          6. Left ventricular ejection fraction≥50%.

          7. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L，platelets (PLT) ≥ 100 × 109/L，hemoglobin
             (Hb) ≥ 90 g/L，leucocyte ≥ 3.0 × 109/L.

          8. Total bilirubin (TBIL) ≤ 1.5 ×institutional upper limit of normal (ULN)， Alanine
             aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) /Aspartate
             aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]≤ 2.5 ×ULN
             ，Creatinine (CRE) ≤ 1.5 ×ULN.

          9. Signed informed content obtained prior to treatment.

        Exclusion Criteria:

          1. Patients who are pregnant or may be pregnant or nursing.

          2. Patients with Coagulation dysfunction or active internal hemorrhage.

          3. Patients with uncontrolled active infection，HIV，viral hepatitis.

          4. Peripheral nerve lesion≥grade 1 following NCI-CTC 5.0.

          5. Patients with serious cardiovasculardisease including history of cerebral vascular
             accident ， myocardial infarction，hypertension，angina，heart failure（NYHA grade 2-4）
             within the last 6 months.

          6. History of allergic reactions attributed to compounds of similar chemical or
             biological composition to drugs used in this study.

          7. Patients was involved in another study within the last 30 days.

          8. Patients was mental disorders.

          9. Any other patients deemed by the attending physician to be unsuitable to allow the
             feasible for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Daping Hospital, Third Military Medical University, Chongqing,China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong Wang, PH.D</last_name>
    <phone>86-23-68757181</phone>
    <email>dongwang64@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Daping Hospital, Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Wang, PH.D.</last_name>
      <phone>86-23-68757151</phone>
      <email>dongwang64@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Dong Wang, PH.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>August 15, 2019</study_first_submitted>
  <study_first_submitted_qc>August 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2019</study_first_posted>
  <last_update_submitted>August 15, 2019</last_update_submitted>
  <last_update_submitted_qc>August 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Dong Wang</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <keyword>Bladder cancer；Paclitaxel-binding albumin；Cisplatin；Neoadjuvant Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

